#biopharmaceuticals #DecipheraPharmaceuticals #Romvimza #tenosynovialgiantcelltumours #TGCT #vimseltinib #FDAapprovel #Deciphera #raretumourtype #symptomatictenosynovialgiantcelltumours #tyrosinekinaseinhibitor #CSF1R #CSF1Rinhibitor #MOTIONclinicaltrial
pharmatimes.com/news/fda-app...
pharmatimes.com/news/fda-app...
FDA approves Deciphera’s Romvimza for rare tumour type - PharmaTimes
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations
pharmatimes.com
February 27, 2025 at 10:02 AM